- GlobeNewswire•2 months agoMadrigal Pharmaceuticals Completes Merger with Synta to Create Leading Cardiovascular-Metabolic Diseases and NASH Company
FORT WASHINGTON, Pa., July 22, 2016-- Madrigal Pharmaceuticals, Inc., a clinical-stage biopharmaceutical company focused on the development and commercialization of innovative therapeutic candidates for ...
- Business Wire•4 months agoSynta Announces Date and Location of Annual Meeting of Stockholders to Vote on Merger with Madrigal Pharmaceuticals
Synta Pharmaceuticals Corp. announced today that the annual meeting of stockholders to approve, among other things, the merger agreement with Madrigal Pharmaceuticals will be held on July 21, 2016, at 9:00 a.m.
MADRIGAL PHARMACEUTICALS INC (SNTA)
NasdaqCM - NasdaqCM Delayed Price. Currency in USD
|Day's Range||0.00 - 0.00|
|1y Target Est||N/A|
Trade prices are not sourced from all markets
|P/E Ratio (ttm)||N/A|
|Avg Vol (3m)||N/A|
|Dividend & Yield||N/A (N/A)|